CRISPR Therapeutics achieved a significant performance milestone by outpacing the industry decline on August 23, 2025.
4 reports, 3 independent
Updated Aug 23
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CRISPR Therapeutics achieved a significant performance milestone by outpacing the industry decline on August 23, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.CRISPR Therapeutics outperformed industry decline on August 23, 2025.1 source
EMA authorized Phase 2 trial of SRSD107 for CRISPR Therapeutics.1 source
Keep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
Nothing else this week.
Related events
- CRISPR Therapeutics and Scribe Therapeutics presented at a Morgan Stanley conference, highlighting their competition in gene-editing therapeutics.
- CRISPR Therapeutics presented durability data on gene therapy at the European Society of Cardiology (ESC) Congress on August 28, 2026.
- CRISPR Therapeutics is discussing commercial priorities and expanding treatment access into new markets with an investment bank.
Coverage
Newest first; wire copies grouped- Simply Wall St.CRISPR Therapeutics (CRSP) Reports Increase In Q2 Revenue Despite Wider Net Losses CRISPR Therapeutics recently reported second-quarter results with a significant year-over-year increase in revenue,
- ZacksCRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of
- GlobeNewswireCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results -CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the t
- ZacksCRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $56.26, marking a -2.46% move